Application of ergothioneine in aspect of preventing depression

Abstract

The invention discloses application of ergothioneine in the aspect of preventing depression, which is specifically characterized in that the ergothioneine has a remarkable effect in the aspect of regulating nervous system functions and can effectively reduce, prevent and relieve the incidence rate of depression symptoms. The action mechanism of the ergothioneine is that the ergothioneine can effectively remove free radicals in a body and reduce damage of oxidative stress to nerve cells, so that the normal function of a nervous system is protected. In addition, the ergothioneine can also promote the balance of neurotransmitters, improve the emotional state and further improve the anti-depression effect. Experimental results provide powerful support for application of ergothioneine in the field of prevention and treatment of depression.

Description

Technical Field

[0001] The invention relates to application of ergothioneine in preventing depression, and particularly relates to the field of health food in preventing depression. Background Art

[0002] Depression is a common psychological disorder that affects a large number of people worldwide. Its main symptoms include low mood, loss of interest, increased fatigue, sleep disorders, changes in appetite, and difficulty concentrating. These symptoms not only affect patients' daily life and work ability, but may also lead to the degradation of social functions and even suicidal thoughts. The pathogenesis of depression is complex, involving multiple aspects such as neurotransmitter imbalance, inflammatory response, genetic factors, and environmental factors. At present, the treatment methods for depression mainly include drug therapy, psychotherapy, and physical therapy, but there are problems such as inconsistent efficacy, obvious side effects, and high recurrence rate. Therefore, finding new and effective antidepressant drugs and treatments has important social value.

[0003] In order to prevent the incidence of depression symptoms, the present invention finds that ergothioneine can inhibit the release of dopamine and norepinephrine in the central nervous system, thereby alleviating the depression symptoms. Summary of the invention

[0004] In order to solve the above-mentioned problems, the present invention provides a natural compound ergothioneine that can prevent and reduce depressive symptoms. In order to better prevent and reduce the occurrence of depressive symptoms, the specific method is as follows:

[0005] The present invention has found that the biological activity of ergothioneine is significantly effective in regulating the function of the central nervous system by in-depth research. As a naturally occurring compound, ergothioneine has a unique chemical structure that enables it to act on the release process of neurotransmitters such as dopamine and norepinephrine, thereby effectively alleviating depression symptoms.

[0006] In specific implementation, the present invention adopts scientific experimental method, verifies the inhibitory effect of thioneine on depressive symptoms. Experimental results show that thioneine can significantly reduce the behavioral index of depression model animals, such as reducing immobility time, increasing exploratory behavior, etc., indicating that it has significant antidepressant effect. Meanwhile, the present invention further explores the mechanism of action of thioneine, and finds that it can play antidepressant effect by regulating neurotransmitter levels, improving inflammatory response and affecting genetic factors and other aspects.

[0007] In addition, the present invention also takes into account the safety and stability of ergothioneine. In order to ensure that it has good safety and stability in practical applications, the inventor and the team adopt a series of behavioral evaluations for the suppression and treatment of corresponding depressive symptoms.

[0008] Further, in the application of the ergothioneine for preventing depression, the ergothioneine for preventing depression specific implementation method includes daily oral ergothioneine supplements, with a dosage range of 50-200 mg, taken twice in the morning and evening. Effect test is carried out after taking it continuously for 30 days, and the dosage is adjusted according to the reaction effect.

[0009] To further understand the improvement of depressive symptoms, the researchers conducted behavioral tests on chronic stress response model mice in model experiments, such as tail suspension immobility time, forced swimming time, elevated plus maze, open field test and other data.

[0010] Furthermore, ergothioneine can significantly reduce the depressive behavior scores of experimental model animals at low doses, and the antidepressant effect becomes more obvious as the dose increases. Specific implementation plan

[0011] The present invention is further described below by way of experimental examples, but the present invention is not limited to the scope of the experimental examples. The experimental methods without specific conditions in the following experimental examples are selected according to conventional methods and conditions, or according to the product instructions.

[0012] Establishment of experimental example of chronic stress depression mouse model:

[0013] All animal experiments involved in this experiment used mice as the model animals for the evaluation of the improvement of depressive symptom therapeutic agents. The animals were 8-week-old C57BL / 6J male mice. The experimental model mice were raised in an environment free of specific pathogens, where the temperature and humidity were controlled at 20-22°C and 45±5%, respectively, and the lighting was set to a 12h light / dark cycle. The specific experimental plan is as follows:

[0014] Grouping and number of mice:

[0015] Normal control group, 10;

[0016] chronic stress group, 10;

[0017] chronic stress + low dose of ergothioneine supplementation, 10;

[0018] chronic stress + high dose of ergothioneine supplement, 10;

[0019] The formation process of the chronic stress group: The mice were subjected to different stimulations every day, including fasting, water deprivation, tail clamping, wet bedding, electrical stimulation, forced swimming, day and night reversal, etc. Each stimulation appeared randomly and lasted for 30 days.

[0020] The following animal models are used for behavioral assessment:

[0021] Behavioral test of tail suspension time in chronic stress-depressed mice and after treatment with ergothioneine supplements (Note: the low dose of ergothioneine is 50 mg / kg, and the high dose of ergothioneine is 200 mg / kg).

[0022] Behavioral test of swimming immobility time in chronic stress-depressed mice and after treatment with ergothioneine supplements (Note: low dose of ergothioneine is 50 mg / kg, high dose of ergothioneine is 200 mg / kg).

[0023] Behavioral test of the open arm residence time in the elevated plus maze in mice with chronic stress depression and after treatment with ergothioneine supplementation (Note: the low dose of ergothioneine is 50 mg / kg, and the high dose of ergothioneine is 200 mg / kg).

[0024] Behavioral test of the center residence time in the open field test in mice with chronic stress depression and after treatment with ergothioneine supplementation (Note: the low dose of ergothioneine is 50 mg / kg, and the high dose of ergothioneine is 200 mg / kg).

[0025] Intervention treatment with ergothioneine supplements: Mice with chronic stress depression were given ergothioneine supplements twice a day (8 am and 8 pm), divided into a low-dose group (50 mg / kg) and a high-dose group (200 mg / kg). The ergothioneine solution was dissolved in water and fed in the morning and evening for 30 days, and their comprehensive behavioral evaluation was observed.

[0026] Behavioral assessment: record the tail suspension immobility time, forced swimming time, elevated plus maze, open field test and other data of each mouse within 5 minutes;

[0027] Experimental Example 1

[0028] For the tail suspension immobility test, the mouse's tail was fixed with tape at the back 1 / 3 and hung on a stand, with the head 15 cm away from the table. The mouse's struggle and immobility behavior were recorded and observed. The timing was stopped after 6 minutes, and the immobility time of the mouse in the last five minutes was counted using small animal behavior analysis software or a timing instrument. The experimental results are shown in Table 1.

[0029] Experimental Example 2

[0030] Further, for the forced swimming test: the mice were slowly placed in a basin filled with an appropriate volume of warm water. The depth of the water was such that the mice could not touch the bottom of the basin. Each mouse was placed in a basin. After the mice had adapted to swimming in the basin for 1 minute, the swimming immobility time of the mice in the following 5 minutes was recorded. After the experiment, the mice were wiped dry and put back into the cage normally. The experimental results are shown in Table 2.

[0031] Experimental Example 3

[0032] Further, for the elevated plus maze experiment: At the beginning of the experiment, the mice were placed in the maze from the central grid to the closed arm, and the activity was recorded within 5 minutes. The observation indicators included: the number of times the open arm entered more than half of the body and the time spent in the open arm, the number of times the closed arm was entered, and the time spent in the closed arm. The proportion of open arm stay time, the proportion of open arm entry times, and the total number of entries in the elevated plus maze were calculated. After the experiment was completed, the mice were taken out, the two arms were cleaned, and alcohol was sprayed to remove the odor left by the previous mice. Finally, the animal behavior software was used for data analysis. The experimental results are shown in Table 3.

[0033] Experimental Example 4

[0034] Further, for the open field experiment: the open field is divided into a central area and an edge area. The mice are placed in the center of the bottom of the box, and video and timing are performed at the same time. The video is stopped after 5 minutes of observation, and the number and time of mice entering the central area and the number and time of mice entering the edge area during this period are recorded. Animal behavior software is used for data analysis. The inner wall and bottom of the round box are cleaned to prevent the smell left by the animal from the last time from affecting the next test result. The experimental results are shown in Table 4.

[0035] Through the above animal behavior data analysis, it can be clearly seen that the overall effect of low-dose ergothioneine supplementation is slightly lower than that of high-dose ergothioneine supplementation.

[0036] At the same time, the corresponding values ​​of the experimental items of chronic stress + low-dose ergothioneine supplementation were close to the normal control group's comprehensive tail suspension immobility time, and the comprehensive data of the chronic stress group was shortened by about 27%; the corresponding values ​​of the experimental items of chronic stress + high-dose ergothioneine supplementation were basically the same as the normal control group's comprehensive time, and the comprehensive data of the chronic stress group was shortened by about 39%. These data fully confirm the significant effect of ergothioneine in preventing depression.

[0037] At the same time, the corresponding values ​​of the experimental items of chronic stress + low-dose ergothioneine supplementation were close to the normal control group's comprehensive forced swimming immobility time, and the comprehensive data of the chronic stress group was shortened by about 27%; the corresponding values ​​of the experimental items of chronic stress + high-dose ergothioneine supplementation were basically the same as the normal control group's comprehensive time, and the comprehensive data of the chronic stress group was shortened by about 50%. These data fully confirm the significant effect of ergothioneine in preventing depression.

[0038] At the same time, the corresponding values ​​of the experimental items of chronic stress + low-dose ergothioneine supplementation were close to the normal control group's comprehensive elevated plus maze open arm stay time, and the comprehensive activity data of the chronic stress group increased by about 0.7 times; the corresponding values ​​of the experimental items of chronic stress + high-dose ergothioneine supplementation were basically the same as the normal control group's comprehensive time, and the comprehensive activity data of the chronic stress group increased by about 1.3 times. These active data fully confirmed that ergothioneine increased the activity of mice after treatment, and performed more stably in stress tests, further improving the anti-depressant effect.

[0039] At the same time, the corresponding values ​​of the chronic stress + low-dose ergothioneine supplement experimental items were close to the normal control group data in the open field experimental center area, and the stability of the comprehensive data of the chronic stress group increased by about 1 times; the corresponding values ​​of the chronic stress + high-dose ergothioneine supplement experimental items were basically close to the normal control group data in the comprehensive time, and the stability of the comprehensive data of the chronic stress group increased by about 1.5 times. These data fully confirm that ergothioneine has the ability to promote the balance of neurotransmitters, improve mood stability, and further enhance the anti-depressant effect.

[0040] This shows that ergothioneine is a natural active ingredient with significant antidepressant effects in preventing depressive symptoms. Its application in the prevention and treatment of depression has broad prospects and is expected to bring new hope to patients with depression.

[0041] At the same time, the application of ergothioneine in preventing depressive symptoms, as the dosage increases within a certain range, the treatment and prevention effects on depressive symptoms become more significant.

[0042] Table 1: Raw data of tail suspension time (unit: seconds)

[0043] Normal control group Chronic stress group Ergothioneine low dose Ergothioneine High Dose 118 185 132 115 135 169 125 106 105 175 133 109 112 206 144 105 96 194 126 116 89 183 132 101 114 176 128 126 108 182 131 104 95 197 145 118 116 184 142 117

[0044] Table 2: Raw data of forced swimming immobility time (unit: seconds)

[0045] Normal control group Chronic stress group Ergothioneine low dose Ergothioneine High Dose 71 145 118 95 82 158 122 86 78 149 124 85 96 176 113 79 102 184 135 68 74 167 128 87 78 166 121 77 68 174 114 83 96 182 127 69 98 168 116 96

[0046] Table 3: Raw data of the time spent in the open arms of the elevated plus maze (unit: seconds)

[0047] Normal control group Chronic stress group Ergothioneine low dose Ergothioneine High Dose 145 65 115 135 148 49 107 144 165 75 98 138 139 62 113 156 147 59 105 147 153 57 102 165 147 46 124 134 156 73 118 128 149 68 95 178 154 72 104 152

[0048] Table 4: Raw data of the residence time in the central area of ​​the open field experiment (unit: seconds)

[0049] Normal control group Chronic stress group Ergothioneine low dose Ergothioneine High Dose 48 15 32 38 35 24 28 42 33 16 25 41 46 8 27 35 38 11 36 29 46 22 33 34 58 13 42 45 41 18 21 34 34 6 23 32 46 7 24 28

Claims

1. The application of ergothioneine in preventing depression is mainly used to prevent, alleviate and treat depressive symptoms.

2. according to described ergothioneine prevention depression aspect, it is characterized in that Ergothioneine can inhibit the release of dopamine and norepinephrine in the central nervous system, thereby relieving symptoms of depression.

3. the ergothioneine according to claim prevents depression aspect, it is characterized in that Ergothioneine Ergothioneine can also promote the growth and repair of neurons, enhance the plasticity of the nervous system, and further improve the symptoms of depression.

4. The application of ergothioneine in preventing depression is not limited to adults, but also shows good application prospects in adolescents and the elderly.

5. according to claim 4, ergothioneine is for teenagers, and ergothioneine helps to relieve learning pressure, improve mood regulation ability, thereby reducing the occurrence of depression.

6. according to claim 4, ergothioneine is for the elderly, and ergothioneine can reduce the risk of senile depression by protecting the nervous system and delaying neurasthenia.